Clinical evaluation of the Makari test in urological malignancies.
The results of a double-blind controlled study of the modified Makari skin test for the detection of cancer are described. The test identified malignant disease in 95% of 37 patients with primary cancer and in 74% of 81 with recurrent cancer after the exclusion of "anergic" patients. The study suggests that the test will be useful in the monitoring of primary treatment and in the detection of recurrent malignancy.